---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-24-000144"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T16:04:59.290897+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pfizer extends vesting and performance periods on 2022/2023 long-term equity awards for ~9,000 employees

## Summary
- Up to 9,000 active employees eligible, including CEO Bourla, CFO Denton, and other named executives.
- 2022 and 2023 TSRUs can be extended for 2 years: settlement now Feb 2029 (2022 grants) and Feb 2030 (2023 grants).
- 2022 and 2023 PSAs can get a 2-year performance period extension, vesting in 2027 and 2028 respectively.
- Modifications aim to restore retention value after COVID-related stock price decline reduced award incentive.
- Election is voluntary via a forthcoming tender offer; all other award terms remain unchanged.

## SEC filing metadata
- accession: 0000078003-24-000144
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/0000078003-24-000144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/pfe-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-24-000144
- JSON: https://secwatch.observer/filing/0000078003-24-000144.json
- Plain text: https://secwatch.observer/filing/0000078003-24-000144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.